Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction

Sponsor
Peking Union Medical College Hospital
Study ID
NCT05918419
Phase
PHASE2
Status
Unknown

Conditions

  • Gastroesophageal Junction Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Investigators conduct the clinical trial to further explore the efficacy and safety of Neoadjuvant chemoradiation Plus Serpluimab in Patients with locally advanced Adenocarcinoma of Gastroesophageal Junction

Key Dates

Start date
Feb 1, 2023
Status verified
Jan 2023
Primary completion
Jun 1, 2024
Completion
Sep 1, 2024

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Neoadjuvant Chemoradiation
    neoadjuvant chemoradiation plus PD-1 antibody (Serplulimab) Intervention: Drug: Neoadjuvant chemoradiation plus PD-1 antibody(Serpluimab)

Primary Outcome Measure

Pathological complete regression (pCR) rate [ Time Frame: 3 months after the last subject participating in ]

Central Contacts

Related Studies